From the Journals

Menstrual irregularity appears to be predictor of early death


 

FROM THE BMJ

Expert suggests a probable underlying link

Dr. Reshef Tal

Dr. Reshef Tal

“Irregular menstrual cycles in women have long been known to be associated with significant morbidities, including the leading causes of mortality worldwide such as cardiovascular disease and cancer,” Reshef Tal, MD, PhD, assistant professor of obstetrics, gynecology & reproductive sciences at Yale University, New Haven, Conn., said in an interview. “The findings of this large study that irregular menstrual cycles are associated with premature death, most strongly from cardiovascular causes, are therefore not surprising.”

Dr. Tal acknowledged that one probable underlying link is PCOS, which is recognized as the most common hormonal disorder affecting women of reproductive age. The irregular periods that characterize PCOS are tied to a number of metabolic risk factors, including obesity, insulin resistance, dyslipidemia, and hypertension, which increase the long-term risk of cardiovascular disease and cancer of the uterus.

“The study did not have information on patients’ pelvic ultrasound findings and male hormone levels, which would have helped to establish PCOS diagnosis. However, women in this study who had irregular cycles tended to have more hirsutism, high cholesterol, hypertension as well as higher BMI, suggesting that PCOS is at least partly responsible for the observed association with cardiovascular disease. Interestingly, the association between irregular cycles and early mortality was independent of BMI, indicating that mechanisms other than metabolic factors may also play a role,” observed Dr. Tal, who was asked to comment on the study.

“Irregular periods are a symptom and not a disease, so it is important to identify underlying metabolic risk factors. Furthermore, physicians are advised to counsel patients experiencing menstrual irregularity, [to advise them to] maintain a healthy lifestyle and be alert to health changes,” Dr. Tal suggested.

The study was funded by the National Institutes of Health. The investigators had no relevant financial disclosures. Dr. Tal said he had no relevant financial disclosures.

SOURCE: Chavarro J et al. BMJ. 2020. doi: 10.1136/bmj.m3464.

Pages

Recommended Reading

Women undergoing hysterectomy, myomectomy have similar short-term outcomes
MDedge Endocrinology
Elagolix is effective second-tier treatment for endometriosis-associated dysmenorrhea
MDedge Endocrinology
How long is it safe to delay gynecologic cancer surgery?
MDedge Endocrinology
COVID-19 experiences from the ob.gyn. front line
MDedge Endocrinology
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
MDedge Endocrinology
Expert clarifies guidance on adolescent polycystic ovary syndrome
MDedge Endocrinology
Appendix may be common site of endometriosis
MDedge Endocrinology
Telemedicine meets menopause in customized patient care service
MDedge Endocrinology
New nonhormonal hot flash treatments on the way
MDedge Endocrinology
Fetal estrogens show promise for safer therapy for menopause
MDedge Endocrinology